Skip to content
HeyJared

Michael Erman

Reporter · US

Indexed articles, last 90 days
3
Latest publication
Aug 28, 2026
Outlet visibility, for Medscape
Top 50K sites
Earliest in this view
Aug 18, 2026
The latest indexed work is over 30 days old. There may be a gap in what we hold.

Latest articles

  1. Article · Aug 28, 2026 · Michael Erman And Julie Steenhuysen

    Success After a Century Of Failures: Inside Moderna and Merck's Cancer Vaccine Breakthrough (opens the original)

    Excerpt · Positive tone · English

    Read excerpt

    Aug 28 (Reuters) - Stephane Bancel, CEO of Moderna, was at a Lebanese restaurant celebrating a friend’s birthday late on August 13 when he got the call. An mRNA cancer vaccine the company had been developing with Merck had hit its mark — the first success of a therapeutic cancer vaccine in late-stage testing after more than 100 years of failed attempts. Cancer experts hailed it as the beginning ⁠of an era of custom-made vaccines that train the immune system to fight an individual patient’s cance

  2. Article · Aug 19, 2026 · Michael Erman And Julie Steenhuysen

    Moderna, Merck Vaccine Cuts Recurrence and Spread Of Melanoma, Raising New Treatment Hope (opens the original)

    Excerpt · Positive tone · English

    Read excerpt

    Aug 19 (Reuters) - Moderna and Merck said on Wednesday that a personalized mRNA cancer vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment that sent Moderna's shares surging as much as 160%. The companies tested the vaccine ⁠together with Merck's immunotherapy drug Keytruda, a widely used melanoma treatment. Thousands of patients who have undergone surgery to remove high-risk melanoma tumors could benefit as soon

  3. Article · Aug 18, 2026 · Michael Erman And Julie Steenhuysen

    US Kindergarten Vaccine Coverage Continues Downward Trend, Falling 0.1% (opens the original)

    Excerpt · Critical tone · English

    Read excerpt

    Aug 17 (Reuters) - U.S. kindergarten vaccination coverage fell 0.1% during the 2025-2026 school year, continuing a downward trend that has seen declines every year except one since the onset of COVID-19, according to data from ⁠the U.S. Centers for Disease Control and Prevention released on Monday. Coverage ranged from 92% for the diphtheria, tetanus and acellular pertussis vaccine (DTaP) to 92.4% for the measles, mumps and rubella vaccine (MMR) and the polio vaccine, the CDC said. The CDC ⁠said

Publishing over time

Last 90 days. Choose a month to open its work.

Recurring subjects

Named in the text we hold. One piece can cover several.

Audience

Top 50K sites

For Medscape, the outlet · Measured Aug 1, 2026

Website popularity band, not a count of readers or article views.

About this data

Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.

Identity or attribution wrong? Suggest a correction.

See coverage about Michael Erman